CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $1.26B, above the global median of $520.53M
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2022 (year ended December 31, 2022). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
44.90BRUB536.12M · vs all stocks (USD)
Revenue (TTM)
105.61BRUB1.26B · vs all stocks (USD)
Profit Margin
0.25%vs Pharmaceutical Retailers peers
52-Week Change
-39.21%vs all stocks
Market Capitalization
44.90BRUB536.12M · vs all stocks (USD)
Enterprise Value
136.94BRUB1.64B · vs all stocks (USD)
Price to Sales (TTM)
0.9028xvs Pharmaceutical Retailers peers
Enterprise to Revenue
1.30xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
11.98xvs Pharmaceutical Retailers peers
Profit Margin
0.25%vs Pharmaceutical Retailers peers
Operating Margin
8.60%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
9.97%vs Pharmaceutical Retailers peers
Revenue (TTM)
105.61BRUB1.26B · vs all stocks (USD)
Revenue per Share (TTM)
14.07RUBUpdated Aug 21, 2026Quarterly Revenue Growth
19.40%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
34.54BRUB412.45M · vs all stocks (USD)
EBITDA (TTM)
10.24BRUB122.34M · vs all stocks (USD)
Net Income (TTM)
263.00MRUB3.14M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
6.70%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
5.07BRUB60.53M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
4.01BRUB47.91M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00RUBUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Pharmaceutical Retailers peers
Revenue
59.05BRUBFY2022 · Dec 31, 2022Cost of Goods Sold
38.85BRUBFY2022 · Dec 31, 2022Gross Profit
20.19BRUBFY2022 · Dec 31, 2022Operating Income
4.79BRUB57.26M · vs all stocks (USD)
Pre-tax Income
411.00MRUBFY2022 · Dec 31, 2022Income Tax Expense
188.00MRUBFY2022 · Dec 31, 2022Net Income
223.00MRUBFY2022 · Dec 31, 2022EBIT
4.65BRUBFY2022 · Dec 31, 2022EBITDA (Income Statement)
10.24BRUBFY2022 · Dec 31, 2022Selling, General & Administrative
1.47BRUBFY2022 · Dec 31, 2022Other Operating Expenses
151.00MRUBFY2022 · Dec 31, 2022Non-operating Interest Income
391.00MRUBFY2022 · Dec 31, 2022Non-operating Interest Expense
4.24BRUBFY2022 · Dec 31, 2022EPS (Basic)
0.0300RUBFY2022 · Dec 31, 2022EPS (Diluted)
0.0292RUBFY2022 · Dec 31, 2022Basic Shares Outstanding
7.63BSharesFY2022 · Dec 31, 2022Diluted Shares Outstanding
7.63BSharesFY2022 · Dec 31, 2022Preferred Stock Dividends
0.00RUBFY2022 · Dec 31, 2022Operating Cash Flow
1.40BRUBFY2022 · Dec 31, 2022Free Cash Flow
704.00MRUBFY2022 · Dec 31, 2022Cash & Cash Equivalents (End of Period)
811.00MRUBFY2022 · Dec 31, 2022Starting Profit (CF Statement)
411.00MRUBFY2022 · Dec 31, 2022Other Non-cash Items
3.83BRUBFY2022 · Dec 31, 2022Change in Accounts Receivable (CF)
-1.06BRUBFY2022 · Dec 31, 2022Change in Other Assets/Liabilities
-1.78BRUBFY2022 · Dec 31, 2022Capital Expenditures
-694.00MRUBFY2022 · Dec 31, 2022Net Intangibles (CF)
-341.00MRUBFY2022 · Dec 31, 2022Net Acquisitions
-291.00MRUBFY2022 · Dec 31, 2022Other Investing Activity
431.00MRUBFY2022 · Dec 31, 2022Net Investing Cash Flow
-554.00MRUBFY2022 · Dec 31, 2022Long-term Debt Issuance
5.90BRUBFY2022 · Dec 31, 2022Long-term Debt Payments
-8.50BRUBFY2022 · Dec 31, 2022Net Financing Cash Flow
-2.60BRUBFY2022 · Dec 31, 2022Shares Outstanding
7.61BSharesUpdated Aug 21, 2026% Held by Insiders
37.49%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
1.36BRUB16.28M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1820RUBUpdated Aug 21, 2026Total Debt (MRQ)
44.47BRUB531.04M · vs all stocks (USD)
Current Ratio (MRQ)
0.5240xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
-0.9720RUBUpdated Aug 21, 2026Total Assets
43.62BRUB520.84M · vs all stocks (USD)
Total Current Assets
14.80BRUBFY2022 · Dec 31, 2022Total Liabilities
50.05BRUBFY2022 · Dec 31, 2022Total Non-current Assets
28.82BRUBFY2022 · Dec 31, 2022Total Non-current Liabilities
22.52BRUBFY2022 · Dec 31, 2022Total Current Liabilities
27.53BRUBFY2022 · Dec 31, 2022Cash
540.00MRUBFY2022 · Dec 31, 2022Cash Equivalents
271.00MRUBFY2022 · Dec 31, 2022Cash & Cash Equivalents
811.00MRUBFY2022 · Dec 31, 2022Accounts Receivable
0.00RUBFY2022 · Dec 31, 2022Inventory
8.48BRUBFY2022 · Dec 31, 2022Accounts Payable
14.64BRUBFY2022 · Dec 31, 2022Short-term Debt
10.28BRUBFY2022 · Dec 31, 2022Other Current Liabilities
228.00MRUBFY2022 · Dec 31, 2022Long-term Debt
22.17BRUBFY2022 · Dec 31, 2022Common Stock (Book)
4.88BRUBFY2022 · Dec 31, 2022Retained Earnings
-55.90BRUBFY2022 · Dec 31, 2022Total Shareholders' Equity
-6.43BRUB-76.79M · vs all stocks (USD)
52-Week Low
4.35RUBUpdated Aug 21, 202652-Week High
9.73RUBUpdated Aug 21, 202652-Week Change
-39.21%vs all stocks
Avg 10-Day Volume
1.92MSharesUpdated Aug 21, 2026Avg 30-Day Volume
4.81MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.0100RUBUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Cash covers reported profit and gross profit is up, with margins high and growth slowing.
Reads
Where is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $1.26B, above the global median of $520.53MNotable
Revenue (USD): 1,261,136,775.528Global Median: 520,528,949.311
Levered free cash flow is $47.91M, above the global median of $16.24MNotable
Levered free cash flow (USD): 47,914,753.883Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Daikokutenbussan Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Citi Trends Inc.
Tier 1FlowUnit ReplicationRiskInterface
Midi Utama Indonesia Tbk PT
Tier 1FlowUnit ReplicationInterfaceProduction
Cachet Pharmaceutical Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
União Pet Participações S.A.
Tier 1FlowUnit ReplicationInterfaceProduction
EVgo, Inc.
Tier 1FlowUnit ReplicationProductionInterface
Tokmanni Group Oyj
Tier 1FlowUnit ReplicationProductionInterface
Jm Holdings Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Haoyun Technologies Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Shanghai Yimin Commerce Development Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceAttention
Companies that share active interpretations — structural patterns currently present in both stocks.
Helios Towers plc
2 interpretationsWithin or Near the Altman Distress ZoneHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Rostelecom Public Joint Stock Company
2 interpretationsWithin or Near the Altman Distress ZoneHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration
Planet Fitness Inc.
2 interpretationsWithin or Near the Altman Distress ZoneHigh OCF-to-NI With Multi-Year Gross-Profit Growth and Elevated-Margin-With-Deceleration